News|Videos|November 20, 2026

Treatment Decisions and Growth Considerations in Pediatric Atopic Dermatitis

Lisa Swanson, MD, explores how pediatric atopic dermatitis, sleep disruption, and dupilumab may influence growth and bone health.

For children with moderate to severe atopic dermatitis (AD), treatment decisions increasingly involve considerations beyond skin clearance and itch reduction. As emerging research explores the relationship between chronic inflammation, growth trajectories, and bone health, clinicians must determine how these findings fit into individualized treatment strategies, particularly for children already tracking at lower height percentiles.

In the third installment of the Dermatology Times Expert Perspectives series, Beyond the Skin: Sleep, Steroids, and Growth in Children With Atopic Dermatitis, Lisa Swanson, MD, examines how growth and skeletal health considerations may influence treatment selection for pediatric patients with AD. The discussion addresses the role of topical therapies, phototherapy, conventional systemic treatments, biologics, and Janus kinase (JAK) inhibitors, as well as the patient characteristics that may warrant closer attention to growth-related outcomes.

As therapeutic options continue to expand across pediatric age groups, incorporating growth monitoring and developmental considerations into AD management may help clinicians better assess the broader burden of disease and individualize care.

Evaluating Growth Concerns in Children With Severe AD

Children with severe AD may experience persistent inflammation, chronic pruritus, sleep disturbances, and substantial impairment in daily functioning. Although these effects are well recognized, their potential relationship with physical growth and skeletal development remains an evolving area of research.

Growth concerns may be particularly relevant for children whose height consistently falls at lower percentiles or whose growth trajectory changes over time.

A retrospective cohort analysis published in 2025 found that children with AD had a greater risk of height below the fifth percentile compared with matched controls (relative risk, 1.15; 95% CI, 1.12-1.18). Although the findings suggest an association between AD and shorter stature, they do not establish that AD directly causes growth impairment.

For clinicians, interpreting growth patterns requires consideration of multiple factors, including age, family growth history, nutritional status, pubertal development, underlying medical conditions, and treatment exposure.

A child who has consistently followed a lower growth percentile may require a different evaluation from one experiencing a decline in height velocity or crossing downward through growth percentiles.

These distinctions become especially important when determining whether growth concerns should influence AD treatment selection or prompt additional evaluation.

Weighing Topical Therapies and Phototherapy

Topical therapies remain foundational to pediatric AD management, particularly for patients with mild to moderate disease or those requiring targeted treatment of inflammatory lesions.

Topical corticosteroids are widely used to control inflammation and reduce pruritus, while nonsteroidal options, including topical calcineurin inhibitors and other approved agents, may provide alternatives or complementary approaches depending on patient age, disease location, and severity.

However, treatment decisions may become more complex in children with extensive or persistent disease requiring frequent corticosteroid application.

Although topical corticosteroids are generally safe when used appropriately, prolonged use of high-potency agents over large body surface areas can increase the potential for systemic absorption. This may be particularly relevant in younger children because of differences in skin surface area relative to body mass.

At the same time, inadequate treatment of severe AD can prolong inflammation, itching, and sleep disruption, potentially contributing to the overall burden of disease.

Phototherapy represents another treatment option for selected patients, although access, treatment frequency, age, and the practical challenges of repeated office visits can limit its feasibility.

For children already experiencing growth concerns, clinicians must weigh these considerations alongside the need for sustained disease control rather than focusing exclusively on medication exposure.

Considering Systemic Therapies in Pediatric Patients

For children with moderate to severe AD that remains inadequately controlled with topical treatment, systemic therapy may be necessary to achieve meaningful and sustained improvements.

The expanding therapeutic landscape includes biologic therapies and oral JAK inhibitors, although available options and approved indications differ according to patient age and other clinical factors.

Dupilumab (Dupixent), which targets interleukin (IL)-4 and IL-13 signaling through inhibition of the IL-4 receptor alpha subunit, is approved for children as young as 6 months with moderate to severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Other systemic options may be appropriate for certain pediatric age groups, depending on regulatory approvals, disease severity, contraindications, and individual patient characteristics.

Conventional systemic immunomodulatory therapies may also be considered in selected circumstances, although their safety profiles and monitoring requirements can influence treatment decisions.

JAK inhibitors provide another therapeutic approach for eligible patients, but their use requires careful consideration of age restrictions, safety warnings, laboratory monitoring, and potential adverse effects.

When evaluating these treatments, clinicians must balance the benefits of effective disease control against medication-specific risks, monitoring requirements, and the long-term needs of developing children.

Where Dupilumab Fits Into Growth-Related Treatment Decisions

Emerging evidence surrounding dupilumab has introduced additional questions about whether effective control of severe AD may be associated with favorable growth-related outcomes.

A 2026 post hoc analysis by Irvine and colleagues evaluated changes in height percentiles and bone alkaline phosphatase (BALP), a marker of bone formation, among children receiving dupilumab.

In children whose baseline height was below the 40th percentile, dupilumab treatment was associated with greater odds of achieving a height percentile increase of at least 5 points compared with placebo at week 16.

The unadjusted odds ratio was 2.5, increasing to 3.1 after adjustment for cumulative topical corticosteroid exposure and 2.9 after adjustment for corticosteroid-free days.

Additional findings from an open-label extension suggested that children who transitioned from placebo to dupilumab experienced growth-related changes similar to those observed among children receiving continuous treatment.

Although these findings are encouraging, the exploratory nature of the analyses limits conclusions about causality. The available evidence does not establish that dupilumab directly stimulates linear growth or improves bone mineral density.

Consequently, growth-related findings should be considered within the broader evidence supporting dupilumab's efficacy and safety rather than as an independent indication for treatment.

For children with severe AD and existing growth concerns, the findings may nevertheless support further discussion about the potential developmental implications of sustained disease control.

Identifying Patients Who May Benefit From Closer Growth Monitoring

Not every child with AD requires the same degree of growth-related evaluation. However, certain clinical characteristics may warrant greater attention to growth trajectories and overall developmental health.

Children with longstanding severe disease, persistent sleep disruption, extensive inflammatory involvement, or frequent treatment escalation may benefit from a more comprehensive assessment of disease burden.

Growth monitoring may be especially important when patients demonstrate declining height velocity, unexpected changes in growth percentiles, or other signs suggesting that development is not progressing as anticipated.

Clinicians should also consider factors beyond AD, including nutritional deficiencies, chronic comorbid conditions, and exposure to medications with potential systemic effects.

Routine review of growth charts, assessment of symptom control, and communication with the child's pediatrician can help distinguish normal developmental variation from patterns requiring additional investigation.

When clinically indicated, referral to pediatric endocrinology or another appropriate specialist may support further evaluation.

Importantly, current evidence does not support routine bone density testing for all children with AD. Decisions about additional testing should reflect individual risk factors and clinical findings.

Integrating Growth and Bone Health Into Long-Term AD Management

As pediatric AD treatment becomes increasingly individualized, growth and bone health may represent additional considerations in evaluating long-term outcomes.

Traditional measures of treatment response, including skin clearance, itch reduction, and improvement in quality of life, remain central to clinical decision-making. However, emerging research suggests that broader developmental outcomes may warrant attention, particularly among children with severe or persistent disease.

Future prospective studies will be needed to determine whether improvements in growth-related biomarkers and height percentiles translate into meaningful long-term differences in skeletal development.

Additional research may also help clarify the relative contributions of inflammation, sleep disruption, corticosteroid exposure, and systemic treatment to observed growth patterns.


Related to this article